Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Revenue remained flat at Rs 7,074 crore, with EBITDA also declining. The company plans upcoming launches to offset revenue decline and drive future growth.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets